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Penn Vet researchers at Pennsylvania’s Equine Toxicology Laboratory have developed the premier program 
for effective testing for artificial substances such as steroids. Read about their work starting on page 4.
B
uilding a faster racehorse: the dream of 
horsemen for hundreds of years, back to the 
days when horseracing was considered the 
sport of kings. As early as 1140, Henry I tried 
to make his “hobby horses” faster and stronger 
by breeding them with Arab stallions brought 
from the Crusades. Obviously, selective breeding has come 
a long way in the intervening centuries toward increasing a 
horse’s natural speed and endurance, but a modern phenomenon 
called “doping”— illegal application of a substance to improve 
a horse’s natural capacities at the time of a race—famously used 
by human athletes, has become a shortcut of choice to create 
a winning horse. Traditionally, the most commonly abused 
substances in horseracing have included anabolic steroids, 
etorphine, narcotic analgesics, erythropoietin (EPO), caffeine, 
beta blockers, butazolidin, bicarb and propantheline bromide. 
All these (along with hundreds of others) have been banned, 
and even substances not on the prohibited list of the Association 
of Racing Commissioners International cannot be administered 
on race day, or sometimes for up to even 30 days before a race. 
Enforcement of the ban requires effective monitoring, detection, 
identification and confirmation methods. Enter Dr. Lawrence 
R. Soma, V’57, Marilyn M. Simpson Professor of Large 
Animal Veterinary Medicine, and Dr. Cornelius E. Uboh, 
adjunct associate professor of pharmacy and pharmacology 
and director of the Pennsylvania Equine Toxicology and 
Research Laboratory (PETRL) in West Chester, Pa. 
How Penn Vet ReseaRcHeRs Put 
tHe BRakes on PeRfoRmance- 
enHancing DRugs in RaceHoRses
By susan i. finkelstein
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The 411 on ePo
In 2006, Drs. Soma and Uboh and their colleagues 
at Penn Vet and PETRL became the first in 
the world to develop a method for confirming 
blood-doping agents—recombinant human 
erythropoietin (rhEPO) and darbepoetin-alfa 
(DPO)—in equine athletes by testing plasma 
through liquid chromatography (separation) and 
mass spectrometry (identification). Previously, 
only the antibodies caused by the drug—not the 
drug itself—were detectable in the blood. Used 
in human and small animal veterinary medicine 
to treat conditions that produce anemia such 
as cancer, and renal disease, EPO is a natural 
hormone protein produced in the kidneys that 
stimulates red blood cell production; rhEPO and 
DPO are genetically engineered versions of EPO. 
These synthetic agents have been abused in human 
endurance sports and horseracing because they are 
difficult to detect and they increase hemoglobin, 
hematocrit concentration (the ratio of the volume 
of packed red blood cells to that of whole blood) 
and maximal oxygen uptake (since red blood 
cells carry oxygen)—hence improving speed and 
endurance time. Not only does use of these agents 
violate rules of fair competition, but deaths in 
equine and human athletes also have been linked to 
them. The potential harmful effects they may have 
on the health of horses are still being investigated, 
but because they are made from human EPO they 
are foreign proteins being administered to animals. 
In other words, they do not naturally belong there. 
One result? “The horses make antibodies 
against the drug. There have been a number of 
deaths because they have been given multiple 
doses,” said Dr. Soma. “Multiple doses in 
one animal seem to build up a resistance that 
suppresses its own naturally occurring [equine] 
EPO, and produces antibodies that can be 
identified, so when you take it away, the horse 
suddenly can become very anemic and crashes. 
There have been some DNA changes, genetic 
changes in the proteins, some amino acid 
changes, endogenous changes, but we haven’t 
been able to figure that out completely yet.”
Although long-term deleterious effects of 
the administration of the human-protein–based 
drugs on horses are still being determined, 
the immediate impact of a positive banned-
substance test on the winners’ purses are very 
much known. In Pennsylvania, blood and urine 
from all first-place winners and horses randomly 
selected at the commonwealth’s six racetracks 
are drawn automatically. The laboratory also 
receives anonymous samples for testing. If a 
horse tests positive, its race victory is voided, 
and the winning purse—which can range from 
$5,000 to $500,000 or more—is awarded to the 
next finisher. In addition to affecting the bottom 
line, violators can also face fines, suspension 
and even license revocation. Inevitably, with 
such high stakes come increasingly sophisticated 
methods by cheaters to beat the system.
“We call them ‘basement chemists.’ They are 
advising the horsemen on what to do,” explained 
Dr. Uboh. “Yes, it is a great challenge for us 
to keep up with the new designer drugs being 
illegally developed. We are working within the 
legal system, meaning that we are looking for 
drugs approved for use; those are the standards we 
have. We can go to the market and buy those, 
but the ones synthesized in basements are not 
publicized, are not out there on the market. We 
can’t buy them. So that’s a challenge we face.”
The Decline of STeroiDS
Because anabolic steroids have become very easy 
to detect via today’s testing protocols, their abuse 
in horseracing has rendered them largely a thing 
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dr. lawrence r. soma, v’57. Photo by sabina louise Pierce.
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of the past. Anabolic and androgenic steroids, 
synthetic forms of the male hormone testosterone, 
have been used to create fitter, powerful and more 
aggressive horses. Corticosteroids (e.g., prednisone 
and dexamethasone), on the other hand, generally 
are used to relieve inflammation in joints and in 
the airways of racehorses. Equine athletes are not 
allowed to receive either type of steroid within 
24 hours of a race (the exception is in Florida, 
where horses can receive the corticosteroid 
prednisolone on race day). The Racing Medication 
and Testing Consortium (RMTC), founded 
in 2000 and governed by a board of directors 
consisting of 23 racing-industry stakeholder groups 
(including the American Association of Equine 
Practitioners and the National Thoroughbred 
Racing Association), has developed a model rule 
regulating use of anabolic steroids in racehorses. 
To date, 24 states (including Pennsylvania, the first 
to go steroid free) have adopted the model rule, 
and nine states are in the process of doing so.
Again a pioneer, PETRL was the first laboratory 
in the world to develop a method of screening, 
quantifying and confirming the anabolic steroids 
in plasma. Making the switch from urine to 
plasma for screening and confirming the presence 
of anabolic steroids made it more rapid and cost 
effective. “Everyone was testing urine because 
it’s a lot easier to get a lot more urine from the 
horse,” said Dr. Uboh. “But if you’re really 
looking for the action of the drug, it’s not what 
is in urine; what it is in plasma matters. If it is 
in urine, the body is sending it out, it doesn’t 
want it. If it’s in plasma—in the blood—then 
it most likely had an effect on the horse.
“Plasma is also cleaner,” Dr. Uboh continued. 
“When you look at the urine result, there are 
so many peaks/signals, so many other naturally 
occurring substances represented by the many 
signals observed. With plasma, it’s very clean. 
If a drug is present, you see one single signal. 
And then you tackle that signal and find an 
answer or identify that peak instead of wasting 
time on so many irrelevant peaks or signals.”
Dr. Soma believes most horsemen are  
glad about the ban. “I think if you talk to the 
average trainer now, he is happy with the ban 
because he says, ‘Now, it’s a level playing field.  
I know my neighbor. He doesn’t have a 
competitive edge on me because he can give 
an anabolic steroid and I don’t want to.’ 
Some trainers didn’t want to give steroids 
but felt forced to because they wouldn’t 
have had that same competitive edge.”
Aside from the unfair impact anabolic steroids 
had on racing, the chemicals also seemed to 
have negative effects on the animals’ behavior, 
akin to the “’roid rage” that can occur in people 
using the substances. “That’s why they’ve been 
banned, finally—because they caused behavioral 
changes,” Dr. Soma explained. “We started 
looking at anabolic steroids about six years ago 
now. The racing commission veterinarians were 
saying, ‘I’ve got horses I can’t handle.’ They 
were having females act like males. If you give 
testosterone to a female, put her out in the 
pasture and there’s another female out there, 
she’s going to act like a stud. And if a gelding is 
given testosterone, he’s going to act like a stud.”
          PeTrl never SleePS
PETRL scientists process 60,000 samples a 
year—equine samples for research, post-race 
and pre-race, as well as from human drivers 
and trainers and occasional “specials” (e.g., if 
a horse expected to win loses, and vice versa, 
or retesting positives from other laboratories). 
Each positive result helps build PETRL’s own 
database of specific drug “fingerprints,” which 
now numbers in the hundreds. Truly, Dr. Uboh 
and his laboratory colleagues have almost single-
handedly rescued the integrity of the horseracing 
industry—in Pennsylvania and beyond.
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“We did some screening in 2005, and 60 
percent of the horses running in Pennsylvania 
had an anabolic steroid in them; some had two 
or three different anabolic steroids,” Dr. Soma 
remembered. In 2008, the Pennsylvania Horse 
Racing Commission and Pennsylvania Harness 
Racing Commission collected 2,061 samples 
during the first two months of the year 2008; 
results showed 98.8 percent of the samples 
were negative, according to the governor’s 
office. Currently all horses in Pennsylvania 
are competing anabolic-steroid–free.
“People think [horseracing] is a very dirty 
industry, nothing but drugs, but that’s not true,” 
said Dr. Uboh. “We know that only about 0.1 
percent test positive. It’s a very clean industry. 
Very well regulated, believe me. Horses are very 
intensely tested. We don’t leave stones unturned. 
Whenever we see something, we pursue it down.”
It is only fitting that such groundbreaking 
work takes place in this commonwealth. 
“Pennsylvania has a proud history of horseracing 
reaching back to the earliest colonists,” said 
Dr. Corinne R. Sweeney, associate dean of 
Penn Vet’s New Bolton Center campus and 
chief operating officer and executive director 
for the George D. Widener Hospital for Large 
Animals. She currently serves as chair of the 
Pennsylvania Horse Racing Commission.
“Pennsylvania’s horse- and harness-racing 
industries are the backbone of our state’s 
$1.5-billion equine industry,” Dr. Sweeney 
continued. “In 1967, the Pennsylvania Horse 
Racing Commission was established, and since then 
Penn Vet has been there, advising the commission 
on issues associated with generating a healthier 
racehorse and implementing a safer racing product.
“Because of the work of Drs. Soma and Uboh, 
the Pennsylvania Horse Racing Commission 
implemented the first ban on anabolic steroids in 
the country, which soon was followed by other 
major racing jurisdictions,” said Dr. Sweeney. 
“The commission continues to turn to these 
Penn scientists to guide us as we eliminate the 
future use of other drugs in the hope to reduce 
catastrophic and lesser racing injuries.”
dr. soma with dr. cornelius e. Uboh. Photo by sabina louise Pierce.
